Loading stock data…
EyePoint (EYPT)
$14.11+0.45 (+3.29%)
Market ClosedLast close Jun 29
EyePoint, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
EyePoint, Inc. in the Healthcare sector is trading at $14.11 with a market capitalization of $1.0B. Wall Street consensus targets $37.00 (12 analysts), implying a +162.2% move over the next 12 months. The stock is currently 26% below its 52-week high of $19.11, remaining 0.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +162.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $696,000↑ | $620,000↓ | $966,000↓ | $5.33M↓ | $24.45M |
| Gross Profit | $168,000↓ | $245,000 | $245,000↓ | $5.17M↓ | $23.65M |
| Operating Income | -$87.23M↓ | -$70.34M↓ | -$62.02M↑ | -$62.23M↓ | -$48.84M |
| Net Income | -$84.83M↓ | -$67.61M↓ | -$59.73M↓ | -$59.43M↓ | -$45.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-117.84%
Volume
Today's trading volume
1.50M
Recent News
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets
EyePoint’s modeled fair value has been adjusted slightly, with the price target moving from US$37.17 to US$37.00 in the latest work. That small change sits against a backdrop of analyst commentary that incorporates Q4 results, Duravyu program updates, and the explicit modeling of the Phase 3 diabetic macular edema program, which is helping frame price targets in the high US$20s to low and mid US$30s. As you read on, you will see how these moving pieces fit together and how to track the...
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness
How EyePoint stock has been trading recently EyePoint (EYPT) has drawn attention after a period of share price pressure, with the stock down about 7% over the past day, 10% over the past week, and 17% over the past month. Despite these shorter term declines, the stock shows a gain of about 101% over the past year and about 90% over the past 3 months. This may prompt investors to reassess how recent trading lines up with the company’s fundamentals. See our latest analysis for EyePoint. At a...